Compare Gilead Sciences, Inc. (GILD) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MGM Resorts International — how do they compare? Gilead Sciences, Inc. trades at $133.4 (market cap $163.51B), while MGM Resorts International trades at $46.71 (market cap $11.98B). The key difference: Gilead Sciences, Inc. is far larger — about 13.6× MGM Resorts International's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MGM | |
|---|---|---|
Market Cap | $163.51B | $11.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $50.69 |
52-Week Low | $108.22 | $30.72 |
Enterprise Value | $178.05B | $41.03B |
Dividend Yield | 2.49% | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
MGM Resorts International (MGM) trades at $46.73, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $48.93. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 2026 missing slightly. The company maintains stable revenue around $17.5 billion but faces declining net profit margins, now at 1.03%. Acquisition interest from Barry Diller at $48.30 per share dominates recent news, potentially driving near-term volatility.
MGM offers moderate upside to the consensus target, supported by takeover speculation and solid cash flow, but high P/E of 64.16 and weak profitability metrics pose valuation risks. Investors should weigh acquisition prospects against fundamental challenges like debt levels and margin pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
